US 11104730
Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
granted A61KA61K38/00A61K38/17
Quick answer
US patent 11104730 (Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Aug 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 26 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 46
- CPC classes
- A61K, A61K38/00, A61K38/17, A61K39/3955, A61P